Latest Safety News

Gorilla Gold has secured critical drilling permits for its Comet Vale Gold Project, enabling exploration on high-priority, previously untested targets and expanding its resource potential. New tenure acquisition further broadens the project’s footprint in Western Australia.

Paladin Energy reported a strong half-year performance with uranium sales revenue climbing to US$138.3 million, driven by ramp-up at its Namibian mine and significant progress on Canadian development projects.

Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.

South32 Limited reported a 29% rise in profit for the half year ended December 2025, driven by higher base and precious metals prices and solid operational performance. The company declared a fully-franked interim dividend and maintained its FY26 production guidance, while advancing key projects and managing portfolio transitions.

Orora Limited reported a robust 32.2% rise in underlying net profit after tax for the half-year ended December 2025, underpinned by strong volume growth in its Cans segment and operational efficiencies across its glass businesses. The company also completed a $227.4 million share buyback in 2025 and announced a fresh $270 million on-market buyback program.

IAG’s 1H26 results reveal a 35% drop in net profit after tax due to severe weather costs from its RACQI acquisition, yet underlying insurance profit rose 7.6%, supported by solid premium growth and a $200 million share buyback.

Paradigm Biopharmaceuticals has published a pivotal study in PLOS ONE showing sustained pain relief and joint repair in dogs treated with pentosan polysulfate sodium, reinforcing its potential for human osteoarthritis therapy.

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.

Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.

Rhythm Biosciences has taken a significant step toward commercialising its ColoSTAT blood test for colorectal cancer by enrolling the first physician in its Access Program, marking the transition from clinical trials to routine clinical use.

Critical Resources Limited has launched a six-month evaluation program in partnership with the South Dakota School of Mines & Technology to develop next-generation solid-state lithium-ion battery materials, aiming to reduce technical risks and accelerate prototype development.

SGH Ltd reported a stable half-year EBIT of $844 million alongside a robust 32% increase in operating cash flow, driven by solid performances at Boral and WesTrac. The company reaffirmed its FY26 guidance amid ongoing operational momentum and strategic initiatives.